Modulation of paraoxonase (PON1) activity

被引:381
作者
Costa, LG
Vitalone, A
Cole, TB
Furlong, CE
机构
[1] Univ Washington, Dept Environm & Occupat Hlth Sci, Seattle, WA 98105 USA
[2] Univ Bari, Dept Pharmacol & Human Physiol, Bari, Italy
[3] Univ Washington, Dept Med Med Genet & Genome Sci, Seattle, WA 98195 USA
关键词
D O I
10.1016/j.bcp.2004.08.027
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Paraoxonase 1 (PON1) is a serum enzyme closely associated with high density lipoprotein (HDL). PON1 hydrolyzes several organophosphorus compounds used as insecticides, as well as nerve agents; it metabolizes toxic oxidized lipids associated with both low density lipoprotein (LDL) and HDL; and it can hydrolyze a number of lactone-containing pharmaceutical compounds, inactivating some, while activating others. Serum PON1 activity in a given population can vary by 40-fold. Though most of this variation can be explained by polymorphisms in the coding region (Q192R) and the 5' regulatory region (T-108C), modulation of PON1 by a variety of other factors should be taken into account, including other polymorphisms recently discovered but not yet characterized. This paper examines the major factors (environmental chemicals, drugs, smoking, alcohol, diet, age, disease conditions) that have been shown to modulate PON1 activity in either direction. As PON1 plays a protective role in organophosphate toxicity, and, because of its antioxidant capacity, in cardiovascular disease, a better understanding of how PON1 can be modulated by environmental factors has potential toxicological and clinical consequences. (C) 2004 Elsevier Inc. All rights reserved.
引用
收藏
页码:541 / 550
页数:10
相关论文
共 102 条
[1]   AGE VARIATION IN PLASMA ARYLESTERASE ACTIVITY IN CHILDREN [J].
AUGUSTINSSON, KB ;
BARR, M .
CLINICA CHIMICA ACTA, 1963, 8 (04) :568-+
[2]   Human serum paraoxonases (PON1) Q and R selectively decrease lipid peroxides in human coronary and carotid atherosclerotic lesions - PON1 esterase and peroxidase-like activities [J].
Aviram, M ;
Hardak, E ;
Vaya, J ;
Mahmood, S ;
Milo, S ;
Hoffman, A ;
Billicke, S ;
Draganov, D ;
Rosenblat, M .
CIRCULATION, 2000, 101 (21) :2510-2517
[3]   Paraoxonase active site required for protection against LDL oxidation involves its free sulfhydryl group and is different from that required for its arylesterase/paraoxonase activities - Selective action of human paraoxonase allozymes Q and R [J].
Aviram, M ;
Billecke, S ;
Sorenson, R ;
Bisgaier, C ;
Newton, R ;
Rosenblat, M ;
Erogul, J ;
Hsu, C ;
Dunlop, C ;
La Du, B .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 1998, 18 (10) :1617-1624
[4]   Human serum paraoxonase (PON 1) is inactivated by oxidized low density lipoprotein and preserved by antioxidants [J].
Aviram, M ;
Rosenblat, M ;
Billecke, S ;
Erogul, J ;
Sorenson, R ;
Bisgaier, CL ;
Newton, RS ;
La Du, B .
FREE RADICAL BIOLOGY AND MEDICINE, 1999, 26 (7-8) :892-904
[5]   Atorvastatin and gemfibrozil metabolites, but not the parent drugs, are potent antioxidants against lipoprotein oxidation [J].
Aviram, M ;
Rosenblat, M ;
Bisgaier, CL ;
Newton, RS .
ATHEROSCLEROSIS, 1998, 138 (02) :271-280
[6]  
Aviram M, 2000, AM J CLIN NUTR, V71, P1062
[7]  
Balogh Z, 2001, DIABETES METAB, V27, P604
[8]  
Beltowski J, 2004, J CARDIOVASC PHARM, V43, P121
[9]   Expression of major HDL-associated antioxidant PON-1 is gender dependent and regulated during inflammation [J].
Bin Ali, A ;
Zhang, Q ;
Lim, YK ;
Fang, D ;
Retnam, L ;
Lim, SK .
FREE RADICAL BIOLOGY AND MEDICINE, 2003, 34 (07) :824-829
[10]   Aspirin use is associated with higher serum concentrations of the anti-oxidant enzyme, paraoxonase-1 [J].
Blatter-Garin, MC ;
Kalix, B ;
De Pree, S ;
James, RW .
DIABETOLOGIA, 2003, 46 (04) :593-594